<DOC>
	<DOC>NCT01566019</DOC>
	<brief_summary>The primary objective of the study is to use high throughput molecular analysis (CGH Array and sequencing) to treat patients with metastatic cancer with targeted therapeutics in order to improve the progression free survival compared to the previous treatment line. The secondary objectives are to investigate clinical practical feasibility of such technics, to potentially improve the overall survival of patients and to describe molecular portrait of Phase 1 candidates.</brief_summary>
	<brief_title>Molecular Screening for Cancer Treatment Optimization</brief_title>
	<detailed_description />
	<criteria>Solid tumors ; Stade IV ; Local relapse or metastatic ; Uncurable Age &gt; 6 months PS 0/1 or Lansky play scale &gt;= 70% Minimum one treatment line, no limit in the prior number of treatment line Evaluable or measurable disease Life expectancy &lt; 3 months Carcinomatous meningitis Symptomatic or progressive radiologic brain metastasis for nonCNS tumors Polynuclear neutrophil &lt; 1 x 10^9/L Platelets &lt; 100 x 10^9/L Hemoglobin &lt; 90 g/L ALT/AST &gt; 2.5 N bilirubin &gt; 1.5 N Creatinine &gt;1.5 N Calcemia &gt; ULN Phosphate &gt; ULN Coagulation anomaly nonindicated for biopsy</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>